IL17A and inflammatory bowel disease: IL-23 and IL-17 show divergent roles on epithelial barrier integrity in experimental models of gut inflammation8,9, which could explain the dichotomy of clinical efficacy of anti-IL-17 vs. IL-12/IL-23 inhibition in IBD patients, even though both are efficacious on joint symptoms in SpA.